trial

Phase IIA Study in Patients With Schizophrenia

NCTId NCT00686998
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 106 (actual)
Sponsored by AstraZeneca
Primary completion 2009-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
106 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-05
Primary completion
2009-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AZD2624Olanzapine

Sponsors

AstraZenecaLead Sponsor

Investigators

1
Dhaval Desai, MDStudy Director

Sites

1 total
Rockville, United States

Linked catalysts

1
Phase IIA Study in Patients With Schizophrenia — primary completion2009-03

Facts & assertions

4 sourced
Enrollment
106
Phase
PHASE2
Primary Completion Date
2009-03
Status
COMPLETED
relationships
The graph out of here
drug
AZD2624
drug
Olanzapine
drug
lead_sponsor
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Dhaval Desai, MD
person